We do a few things, but those few things must be the best in the world: Novo Nordisk’s top exec

Maziar Mike Doustdar, executive VP, Novo Nordisk; image credit: Company


Novo Nordisk, the most valuable pharmaceutical company in the world, turned 100 last year. While it is largely known for its insulins, its anti-obesity drugs are making waves of late. Maziar Mike Doustdar, executive vice-president, international operations at Novo Nordisk tells ET Prime the beliefs that distinguish the company.

Danish pharmaceutical company Novo Nordisk celebrated its centenary last year. Yet, it has mostly kept a low profile. Known for a spectrum of insulins, the company has retained a strong grip on its market share. But a big surprise was in store beyond insulins. After two decades of research by its scientists, Novo Nordisk landed a remarkable feat. First Ozempic and then Wegovy, the two drugs were found very effective in cutting obesity. The

  • SAVE

Uh-oh! This is an exclusive story available for selected readers only.

Worry not. You’re just a step away.

Why ?

  • Exclusive Economic Times Stories, Editorials & Expert opinion across 20+ sectors

  • Stock analysis. Market Research. Industry Trends on 4000+ Stocks

  • Clean experience with
    Minimal Ads

  • Comment & Engage with ET Prime community

  • Exclusive invites to Virtual Events with Industry Leaders

  • A trusted team of Journalists & Analysts who can best filter signal from noise

  • ​Get 1 Year Complimentary Subscription of TOI+ worth Rs.799/-​

Leave a Reply

Your email address will not be published. Required fields are marked *